Quantcast

New Scientific Studies Reveal BergaMet(TM) Strikingly Effective for Epidemic Fatty Liver Conditions

January 27, 2014

New Hope for Fatty Liver Disease Sufferers: BergaMet(TM) citrus bergamot extract now proven effective for patients with NAFLD

DENVER, Jan. 27, 2014 /PRNewswire/ — Two separate studies conducted in Italy reveal that a highly concentrated proprietary extract of the Calabrian bergamot fruit (38% citrus bergamot extract, BergaMet(TM)/NatHealthsolutions) powerfully benefits patients with nonalcoholic fatty liver disease (NAFLD). Previous research has shown BergaMet(TM) to be a powerful cholesterol and metabolic regulator that routinely improves vascular health.

(Photo: http://photos.prnewswire.com/prnh/20140127/PH52618-a )

(Photo: http://photos.prnewswire.com/prnh/20140127/PH52618-b )

Dr. James Ehrlich of the University of Colorado believes this “exciting new area of research” suggests an important additional indication for BergaMet(TM) that could improve the lives of millions. “BergaMet(TM) may be the most versatile and important natural supplement ever developed. We have been impressed by its safety and its clinical value for individuals with conditions ranging from metabolic syndrome to high cholesterol to statin intolerance and obesity. The present investigations show great promise that hepatic steatosis (NAFLD), a highly prevalent and important condition can finally be effectively addressed by a safe commercially available product.”

Nonalcoholic fatty liver disease (NAFLD) is the most prevalent liver abnormality in Western countries (20-30%) and parallels the epidemic of metabolic syndrome, obesity and diabetes. Frequently disabling and occasionally leading to cirrhosis, fatty liver disease has been difficult to treat. Although anti-oxidant vitamin E is helpful in a minority of patients, there remains an intense search for natural and safe supplements that might ameliorate the condition, decrease hepatic fat and improve liver function abnormalities.

In a study conducted by Professor G. Rosano (San Raffaelle Pisana Clinic, Rome) involving investigators from the US, Australia and the University of Catanzaro (led by Professor V. Mollace), 107 patients with metabolic syndrome and NAFLD were treated for 120 days with polyphenol-rich 38% citrus bergamot extract (BergaMet(TM)). In addition to the expected significant improvements in cholesterol levels, lipid particle characteristics, blood sugar and inflammation, there was a strikingly positive effect on both liver function and structure. Ultrasound of abdominal structures (“hepatorenal ratio”) revealed a dramatic 50% reduction in liver fat, while a biochemical analysis (“steato test”) demonstrated a 40% improvement in scores. Bergamot therapy converted the typical patient from severe steatosis (fatty liver) to the moderate category in 12 weeks. Standard liver function blood tests also quickly normalized in the majority of patients.

Undoubtedly, this study will be among several new research contributions presented at the next international conference on bergamot polyphenols led by Professor Vincenzo Mollace of the University of Catanzaro. He notes “our studies in both rats and humans have consistently demonstrated that therapy with bergamot counters the accumulation of fat in the liver while completely prompting its elimination.”

A separate group of investigators led by Professor F. Andreozzi (Polyclinico Umberto I, Rome) evaluated an “integrator” (Tokaber) consisting of citrus bergamot extract/oleo european/ascorbic acid given to 40 patients with fatty liver disease for a period of 60 days. As has been shown previously, the study demonstrated significant improvements in lipid levels, insulin resistance, visceral fat/waist circumference and endothelial health (vascular function). In addition, highly significant improvements in liver function tests were demonstrated in this study.

“We are doing our best to educate the practicing physician and the proactive consumer to the expanding utility of our patented product, BergaMet(TM) and why it is the only scientifically validated bergamot extract on the market” states Selwyn Barr. “As the CEO of Nathealthsolutions, the worldwide distributor of BergaMet (TM)products, we are excited with the latest studies on the effects of BergaMet on NAFLD and lipid particle size. This is an additional benefit, adding to the substantial ones already present”.

Each BergaMet MEGA bottle contains 60 tablets, each containing 650 mg of pure bergamot dehydrated juice and 50 mg of ascorbic acid. Recommended dosage is one tablet twice daily, 20 to 30 minutes before the two largest meals of the day. BergaMet is also available to single or small group practices as BergaMetPro. For more information or to order online, visit www.bergamet.com.

About Nathealth Solutions

Nathealthsolutions is the U.S.-based distributor of BergaMet MEGA and BergaMet PRO, the most powerful, natural agents for the management of lipid/metabolic disorders. Derived from the Citrus Bergamia Risso (bergamot) plant in the Calabria region of Southern Italy, BergaMet(TM) is the only product, drug or supplement that effectively addresses all the components of metabolic syndrome. BergaMet(TM) also acts as a powerful antioxidant, lowers blood glucose levels, reduces blood pressure and reduces triglycerides while improving artery health.

For more information, visit www.bergamet.com or call 855-556-2131. Find us on Facebook at www.facebook.com/Bergamet.

Read more news from Nathealth Solutions.

SOURCE Nathealth Solutions


Source: PR Newswire



comments powered by Disqus